The Health Secretary reported 322 new deaths from Covid-19 this Thursday, so the official number of deaths in Mexico due to the pandemic increased to 285,669.
The number accumulated contagions of the new coronavirus in Mexico increased to 3 million 772,556, after registering 4,798 new confirmed cases.
In the daily technical report on the progress of the epidemic in the country on October 21, it was detailed that federal health authorities have an estimated 33,880 active cases, that is, people who presented symptoms of this disease in the last 14 days. While the estimated number of infections is 3 million 991,476, according to the percentage of positivity registered in epidemiological week 40 of 2021; It should be remembered that the current epidemiological week is 43.
The federal agency reported that the occupation of general beds for the care of patients with SARS-CoV-2 coronavirus is 23%, one percentage point less than what was registered yesterday. Meanwhile, the occupancy of beds with a fan stands, unchanged, at 21 percent.
Progress of vaccination against Covid-19 in Mexico
At the cutoff on Wednesday, October 20, the Ministry of Health piled up 450,121 vaccines against Covid-19, to register a total of 113 million 471,215 doses applied since the vaccination strategy began in the country on December 24, 2020.
The federal government highlighted that 69 million 612,911 people, which is equivalent to 88% of the population over 18 years of age, have been inoculated with at least one dose. Thus, 52 million 117,827 (25%) have the complete scheme with one or two doses, depending on the type of vaccine applied. While 17 million 495,084 (25%) people are still waiting to complete their vaccination schedule.
CDMX will begin to vaccinate minors with comorbidities
The government of the Mexico City announced that next week it will begin with the application of the vaccine against Covid-19 for minors with comorbidities, according to the National Vaccination Plan.
The head of Government of the CDMX, Claudia SheinbaumHe recalled that doses of the vaccine developed by Pfizer and BioNTech will be used.
Last september, Pfizer and BioNTech claimed their vaccine induced a robust immune response in children ages 5 to 11, and they planned to apply for permission to use the vaccine in children in that age range in the United States, Europe, and elsewhere as soon as possible.
The companies claimed that the vaccine elicited an immune response in children of that age range in their Phase II / III clinical trial that matched what they had previously observed in people ages 16 to 25. The safety profile is also generally comparable to that of the older age group, they said.
kg
Reference-www.eleconomista.com.mx